Suppr超能文献

溶菌酶这种溶壁酶对内源细菌细胞壁聚合物的降解可防止具有实验性肠道细菌过度生长的遗传易感大鼠发生肝胆损伤。

Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth.

作者信息

Lichtman S N, Okoruwa E E, Keku J, Schwab J H, Sartor R B

机构信息

Department of Pediatrics, University of North Carolina, Chapel Hill 27599-7220.

出版信息

J Clin Invest. 1992 Oct;90(4):1313-22. doi: 10.1172/JCI115996.

Abstract

Jejunal self-filling blind loops with subsequent small bowel bacterial overgrowth (SBBO) induce hepatobiliary injury in genetically susceptible Lewis rats. Lesions consist of portal tract inflammation, bile duct proliferation, and destruction. To determine the pathogenesis of SBBO-induced hepatobiliary injury, we treated Lewis rats with SBBO by using several agents with different mechanisms of activity. Buffer treatment, ursodeoxycholic acid, prednisone, methotrexate, and cyclosporin A failed to prevent SBBO-induced injury as demonstrated by increased plasma aspartate aminotransferase (AST) and elevated histology scores. However, hepatic injury was prevented by mutanolysin, a muralytic enzyme whose only known activity is to split the beta 1-4 N-acetylmuramyl-N-acetylglucosamine linkage of peptidoglycan-polysaccharide (PG-PS), a bacterial cell wall polymer with potent inflammatory and immunoregulatory properties. Mutanolysin therapy started on the day blind loops were surgically created and continued for 8 wk significantly diminished AST (101 +/- 37 U/liter) and liver histology scores (2.2 +/- 2.7) compared to buffer-treated rats (228 +/- 146 U/liter, P < 0.05, 8.2 +/- 1.9, P < 0.001 respectively). Mutanolysin treatment started during the early phase of hepatic injury, 16-21 d after surgery, decreased AST in 7 of 11 rats from 142 +/- 80 to 103 +/- 24 U/liter contrasted to increased AST in 9 of 11 buffer-treated rats from 108 +/- 52 to 247 +/- 142 U/liter, P < 0.05. Mutanolysin did not change total bacterial numbers within the loop, eliminate Bacteroides sp., have in vitro antibiotic effects, or diminish mucosal PG-PS transport. However, mutanolysin treatment prevented elevation of plasma anti-PG antibodies and tumor necrosis factor-alpha (TNF alpha) levels which occurred in buffer treated rats with SBBO and decreased TNF alpha production in isolated Kupffer cells stimulated in vitro with PG-PS. Based on the preventive and therapeutic activity of this highly specific muralytic enzyme, we conclude that systemic uptake of PG-PS derived from endogenous enteric bacteria contributes to hepatobiliary injury induced by SBBO in susceptible rat strains.

摘要

空肠自充盈盲袢伴随后续小肠细菌过度生长(SBBO)会在基因易感的Lewis大鼠中诱发肝胆损伤。损伤包括门管区炎症、胆管增生和破坏。为了确定SBBO诱导的肝胆损伤的发病机制,我们使用几种具有不同作用机制的药物对Lewis大鼠进行SBBO治疗。缓冲液处理、熊去氧胆酸、泼尼松、甲氨蝶呤和环孢素A均未能预防SBBO诱导的损伤,血浆天冬氨酸转氨酶(AST)升高和组织学评分升高证明了这一点。然而,变溶菌素可预防肝损伤,变溶菌素是一种溶壁酶,其唯一已知的活性是裂解肽聚糖 - 多糖(PG - PS)的β1 - 4 N - 乙酰胞壁酰 - N - 乙酰葡糖胺连接,PG - PS是一种具有强大炎症和免疫调节特性的细菌细胞壁聚合物。与缓冲液处理的大鼠(分别为228±146 U/升,P < 0.05,8.2±1.9,P < 0.001)相比,在手术创建盲袢当天开始并持续8周的变溶菌素治疗显著降低了AST(101±37 U/升)和肝脏组织学评分(2.2±2.7)。在肝损伤早期,即手术后16 - 21天开始变溶菌素治疗,11只大鼠中有7只的AST从142±80降至103±24 U/升,相比之下,11只缓冲液处理的大鼠中有9只的AST从108±52升至247±142 U/升,P < 0.05。变溶菌素并未改变盲袢内的细菌总数,未消除拟杆菌属,没有体外抗生素作用,也未减少黏膜PG - PS转运。然而,变溶菌素治疗可预防SBBO缓冲液处理大鼠中出现的血浆抗PG抗体和肿瘤坏死因子 - α(TNFα)水平升高,并降低体外PG - PS刺激的分离枯否细胞中TNFα的产生。基于这种高度特异性溶壁酶的预防和治疗活性,我们得出结论,内源性肠道细菌衍生的PG - PS的全身摄取促成了易感大鼠品系中SBBO诱导的肝胆损伤。

相似文献

4
Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth.
Gastroenterology. 1990 Feb;98(2):414-23. doi: 10.1016/0016-5085(90)90833-m.
7
A microcholangiographic study of liver disease models in rats.
Acad Radiol. 1995 Jun;2(6):515-21. doi: 10.1016/s1076-6332(05)80410-6.

引用本文的文献

8
Biliary Mucosal Barrier and Microbiome.胆道黏膜屏障与微生物群
Viszeralmedizin. 2015 Jun;31(3):156-61. doi: 10.1159/000431071. Epub 2015 Jun 5.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验